Companies · Pharma
FORT WORTH · Pharma · refined from filed group “Other Health Care” · https://osteonholdings.com/services/
Diligence memoA one-page analyst read on Osteon Holdings, Inc. — recommendation, valuation, rhythm, risks.→Osteon Holdings, Inc. has raised $617M over 1 round; too few niche peers to rank its valuation yet.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.
Osteon Holdings, Inc. behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Osteon Holdings, Inc. is one of 310 Pharma companies tracked from FORT WORTH. By capital raised it ranks among the largest (ahead of 100% of sector peers), and among the largest by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%
operates a technology-led product inferred from public copy
Grounded in: “You are a venture analyst”
Services – Osteon Holdings
Osteon Holdings is a multi-industry company with a global presence, offering premium products and solutions across Food, Healthcare, FMCG, Lifestyle, Metals, and Construction. With strong distribution networks and trusted partnerships, we are committed to delivering quality and innovation. We source 100% natural, premium products worldwide. With advanced food engineering and farmer partnerships, we ensure pure, chemical-free, and beautifully packaged superfoods Delivering durable, high-quality medical equipment with patient care at the core of our mission. Driving sustainable global trade, our Agro division ensures food security through reliable sourcing and re-export of premium commodities. Creating meaningful lifestyle experiences that exceed expectations and build long-term value for customers, employees, and partners. Trusted suppliers of innovative and genuine pharmaceutical products, meeting the highest standards of quality. Supplying high-quality construction materials and equipment, supporting the region’s infrastructure growth and development. Osteon Foods believes in offering 100% natural and premium quality products. With 15+ years of Smart Food Engineering experience an
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A, Series B, Series C, Series D+ — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 14%.
Round size and date are reported; the stage label is inferred from round size (latest is Growth/Late — a round over $400M). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 310 companies in Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 100% of sector peers (real $). Modeled value above 100% of peers (estimate).
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Growth/Late | $617.0M | 2018-02-14 | $6.2B | $22.4B | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Kendall Garrison | — | 6 other | 2018-02 |
| John Schilling | — | 5 other | 2018-02 |
| CLIVE BODE | — | 3 other | 2018-02 |
| STEVEN A. WILLMANN | — | 3 other | 2018-02 |
| Jeffrey Binder | — | 2 other | 2018-02 |
| Joann Harris | — | 2 other | 2018-02 |
| Ken Murphy | — | 2 other | 2018-02 |
| Todd Sisitsky | — | 2 other | 2018-02 |
| ADAM FLISS | — | 1 other | 2018-02 |
| MARTIN A. DAVIDSON | — | 1 other | 2018-02 |
| MICHAEL LAGATTA | — | 1 other | 2018-02 |
| DAVID PETTY | — | — | 2018-02 |
| WILLIAM PETTY | — | — | 2018-02 |
Osteon Holdings, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| EP Global Production Solutions Investment, LLC | Business Services | Series C | $68.8M | $1.6B | network5 shared operators |
| Monogram Health Holdings, Inc. | Healthtech | Series D+ | $535.1M | $5.5B | network2 shared operators |
| TPG Valley, L.P. | Pharmaceuticals | Series A | $7.3M | $224.5M | network3 shared operators |
| Arkady HoldCo, Inc. | Other | Growth/Late | $1.4B | $15.3B | network1 shared operator · same stage |
| KSMS Holdings, LLC | Other Health Care | Series B | $40.0M | $885.1M | network2 shared operators |
| Mirador Therapeutics, Inc. | Pharma | Series D+ | $413.0M | $4.0B | same sector |
| Kelsey-Seybold Medical Group, PLLC | Hospitals and Physicians | Series A | $14.2M | $267.0M | network2 shared operators |
| Aimmune Therapeutics, Inc. | Pharma | Series D+ | $334.7M | $3.5B | same sector |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Osteopathics Limited British private limited company, based in Radlett. Sector: Healthcare. | Healthcare | — | — | 74% |
| OS1 Holdings, Inc. | Other Health Care | Seed | $1.2M | 74% |
| Osseo Regenerative Technologies (uk) LTD British private limited company, based in Cardiff. Sector: Healthcare. | Healthcare | — | — | 74% |
| Alto Pharmacy Holdings, Inc. | Biotech / Pharma | Series D+ | $3.1B | 73% |
| AION Healthspan, Inc. | Pharmaceuticals | Seed | $28.5M | 73% |
| Olam Holdings, Inc. Explore the food ingredients and agricultural commodities Olam offers customers around the world through our global footprint and team of experts. | Agriculture | Growth/Late | $13.9B | 73% |
| Osmol Therapeutics, Inc. | Biotechnology | Seed | $41.6M | 72% |
| Ostentus Therapeutics, Inc. | Pharma | Pre-Seed | $835K | 72% |
See where Osteon Holdings, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Osteon Holdings, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.